Form D · Biotechnology
Sulfagenix, Inc.
Chesterland, OH · CIK 0001603985
Offering snapshot reported Dec 27, 2016 · SEC filing
- Reported sold
- $1.35M Offering amount: $1.62M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Nov 13, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 27, 2016 | Initial | $1,349,591 | No comparison | 2 | SEC filing |
| Mar 31, 2014 | Initial | $1,300,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-277073
Series A-1 Convertible Preferred Stock
Source: Form D, filed Dec 27, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Anthony Giordano | Director, Executive |
| Gabriel Gojon, Jr. | Director |
| Cesar Vidales | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
7515 Cedar Rd.
Chesterland, OH, 44026
Chesterland, OH, 44026